The Claim
Rare loss-of-function variants in the ANGPTL7 gene are associated with a 5.2% to 26.5% reduction in intraocular pressure in human carriers, depending on zygosity, and are linked to a 23% lower risk of glaucoma.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
People with rare genetic changes that reduce ANGPTL7 gene function have lower intraocular pressure and a lower risk of developing glaucoma compared to those without these variants.
See the scientific wording
Rare loss-of-function variants in the ANGPTL7 gene are associated with a 5.2% to 26.5% reduction in intraocular pressure in human carriers, depending on zygosity, and are linked to a 23% lower risk of glaucoma, suggesting that reduced ANGPTL7 function may protect against elevated intraocular pressure and glaucoma development.
When the ANGPTL7 protein is reduced, the drainage system in the eye becomes less clogged because less structural material builds up around the outflow channels. This allows fluid to drain more easily, which lowers pressure inside the eye and reduces the chance of damage that leads to glaucoma.
What the research says
1 studyStudy: ANGPTL7, a therapeutic target for increased intraocular pressure and glaucoma
People born with broken copies of the ANGPTL7 gene have lower eye pressure and are much less likely to get glaucoma. Scientists confirmed this by removing the gene in mice, which also lowered their eye pressure — proving the gene plays a key role in eye pressure control.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.